We are live on ! Find out more
VM

VHCP Management Portfolio holdings

AUM $93M
1-Year Est. Return 10.04%
This Fund
S&P 500
This Quarter Est. Return
-7.09%
1 Year Est. Return
-10.04%
3 Year Est. Return
+233.99%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$96.5M
AUM Growth
-$18.7M
Cap. Flow
-$5.48M
Cap. Flow %
-5.68%
Top 10 Hldgs %
85.26%
Holding
24
New
1
Increased
2
Reduced
–
Closed
1

Top Buys

Rank Stock Value
1
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$1.37M
2
ARCT icon
Arcturus Therapeutics
ARCT
+$625K
3
SYRE icon
Spyre Therapeutics
SYRE
+$46K

Top Sells

Rank Stock Value
1
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
+$7.52M

Sector Composition

Rank Sector Weight
1 Healthcare 67.96%
2 Miscellaneous 32.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HRTX icon
1
Heron Therapeutics
HRTX
$63M
$19.8M 20.5%
1,095,734
– –
CHRS icon
2
Coherus Oncology
CHRS
$226M
$10.3M 10.69%
611,010
– –
AVDL
3
DELISTED
Avadel Pharmaceuticals
AVDL
$5.37M 5.57%
500,000
– –
LRMR icon
4
Larimar Therapeutics
LRMR
$421M
$3.61M 3.74%
50,176
– –
ADVM
5
DELISTED
Adverum Biotechnologies
ADVM
$3.48M 3.61%
110,274
– –
BCRX icon
6
BioCryst Pharmaceuticals
BCRX
$2.52B
$2.85M 2.96%
1,005,104
+442,161
+79% +$1.37M
ARCT icon
7
Arcturus Therapeutics
ARCT
$460M
$2.8M 2.9%
89,045
+19,831
+29% +$625K
LPCN icon
8
Lipocine
LPCN
$18.4M
$2.58M 2.68%
49,995
– –
SIOX
9
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$2.36M 2.45%
23,014
– –
AKTX
10
Akari Therapeutics
AKTX
$17.5M
$2.14M 2.21%
198
– –
ONC
11
BeOne Medicines Ltd
ONC
$42.1B
$1.52M 1.58%
51,000
– –
OCRX
12
DELISTED
Ocera Therapeutics, Inc.
OCRX
$1.51M 1.57%
796,550
– –
PDSB icon
13
PDS Biotechnology
PDSB
$12.2M
$1.36M 1.41%
6,750
– –
ORKA
14
Oruka Therapeutics
ORKA
$6.39B
$1.34M 1.39%
2,141
– –
GBT
15
DELISTED
Global Blood Therapeutics, Inc.
GBT
$1.21M 1.26%
72,990
– –
ASND icon
16
Ascendis Pharma A/S
ASND
$16.4B
$1.19M 1.24%
90,000
– –
STML
17
DELISTED
Stemline Therapeutics, Inc.
STML
$917K 0.95%
135,420
– –
CTMX icon
18
CytomX Therapeutics
CTMX
$745M
$656K 0.68%
64,200
– –
RGNX icon
19
Regenxbio
RGNX
$619M
$420K 0.44%
52,500
– –
SRRA
20
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$112K 0.12%
1,401
– –
SYRE icon
21
Spyre Therapeutics
SYRE
$8.25B
$29K 0.03%
+240
New +$46K
ANAC
22
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
– –
-140,756
Closed -$7.52M

Similar funds

QGI
Quadrangle GP Investors New York $93.6M AUM 10.64% 1-Year Est. Return
KC
Kanha Capital New York $89.9M AUM
RSCM
Rail-Splitter Capital Management Chicago, Illinois $89.4M AUM 15.13% 1-Year Est. Return
ZC
Zelman Capital Beachwood, Ohio $81.9M AUM 22.32% 1-Year Est. Return
TF
Trutina Financial Bellevue, Washington $76.7M AUM 19.34% 1-Year Est. Return
SAM
Sunnymeath Asset Management Red Bank, New Jersey $71.2M AUM 26.57% 1-Year Est. Return
NA
NS Advisors Westport, Connecticut $71M AUM 25.21% 1-Year Est. Return
NCIM
New Century Investment Management Southfield, Michigan $70.5M AUM 23.2% 1-Year Est. Return

VHCP Management's Q2 2016 Portfolio in Review

As of Q2 2016, VHCP Management held 24 positions worth $96.5M, down 16% from $115M the previous quarter. Its ten largest holdings account for 85% of the portfolio.

VHCP Management withdrew a net $5.48M in Q2 2016, closing 1 position. Its most notable exit was ANACOR PHARMACEUTICALS INC COM, an estimated $7.52M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 68% of assets, up from 67% a quarter earlier, followed by Miscellaneous.

Against the trend, VHCP Management opened a new position in Spyre Therapeutics worth $29K.

  • VHCP Management's largest Q2 2016 buy was Spyre Therapeutics: 240 shares worth $29K.
  • VHCP Management added most to BioCryst Pharmaceuticals in Q2 2016, an estimated $1.37M increase.
  • VHCP Management fully exited ANACOR PHARMACEUTICALS INC COM in Q2 2016, selling an estimated $7.52M.
  • VHCP Management's ten largest holdings make up 85% of its $96.5M portfolio in Q2 2016.
  • VHCP Management opened 1 new position and closed 1 in Q2 2016.
  • VHCP Management's portfolio value fell 16% quarter-over-quarter to $96.5M.

Based on VHCP Management's 13F filing for Q2 2016, filed 12 Aug 2016.